Sugi Predict

Sugi Predict / Compounds / SCHEMBL3326531

SCHEMBL3326531

SCHEMBL3326531

COc1ccc(CN2CCOCC2=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ GAA P10253 2/20 0.52
▸ CMA1 P23946 1/20 0.49
▸ MAPK1 P28482 1/20 0.48
▸ GRM2 Q14416 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ FKBP1A P62942 1/20 0.47
▸ GSK3A P49840 2/20 0.46
▸ GSK3B P49841 2/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ EPAS1 Q99814 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ APOBEC3G Q9HC16 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15723517 0.87 SMN1; SMN2 (0.61) SMN1; SMN2GAACMA1MAPK1GRM2
SCHEMBL29181490 0.86 SMN1; SMN2 (0.60) SMN1; SMN2GAACMA1MAPK1GRM2
SCHEMBL31043770 0.83 HIF1A (0.52) MAPK1HIF1AEPAS1ALDH1A1MAPT
SCHEMBL13299412 0.83 SMN1; SMN2 (0.49) SMN1; SMN2GRM2TSHRALDH1A1MAPT
SCHEMBL4234823 0.82 KLKB1 (0.42) SMN1; SMN2GRM2TSHRALDH1A1
SCHEMBL20425267 0.81 JAK2 (0.43) GRM2L3MBTL1
SCHEMBL23269469 0.80 KMT2A (0.46) SMN1; SMN2GRM2L3MBTL1ALDH1A1MEN1
SCHEMBL8325711 0.80 GRM2 (0.54) SMN1; SMN2GRM2L3MBTL1ALDH1A1MAPT
SCHEMBL79013 0.80 GRM2 (0.43) GRM2L3MBTL1ALDH1A1
SCHEMBL1553262 0.80 L3MBTL1 (0.54) CMA1L3MBTL1FKBP1AGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745129-A2 COMPOUND HAVING CYCLIC STRUCTURE Daiichi Sankyo Company, Limited (JP) 2026-05-20 — — EP disclosed
US-12297187-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-05-13 — — US disclosed
US-20240150362-A1 Substituted Pyrrolotriazines MOLECURE S.A. (PL) 2024-05-09 — — US disclosed
WO-2024042494-A1 SUBSTITUTED PYRROLOTRIAZINES MOLECURE SA (PL) 2024-02-29 — — WO disclosed
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 — — US disclosed
CN-111094255-B Compounds having cyclic structures 第一三共株式会社 2023-10-03 — — CN disclosed
US-11512067-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-11-29 — — US disclosed
EP-3985001-A1 PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1 Les Laboratoires Servier SAS (FR) 2022-04-20 — — EP disclosed
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
EP-3682881-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-07-22 — — EP disclosed
WO-2005105100-A1 MORPHOLINE COMPOUNDS PFIZER LIMITED (GB) 2005-11-10 — — WO disclosed
US-20050250775-A1 Novel compounds FISH PAUL V 2005-11-10 — — US disclosed
US-6958402-B2 3-(imidazolyl)-2-alkoxypropanoic acids PFIZER, INC. (US) 2005-10-25 — — US disclosed
CN-1620291-A 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors PFIZER (US) 2005-05-25 — — CN disclosed
US-20040254164-A1 3-(imidazolyl)-2-alkoxypropanoic acids PFIZER INC. (US) 2004-12-16 — — US disclosed
EP-1467731-A1 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS Pfizer Limited (GB) 2004-10-20 — — EP disclosed
US-6713496-B2 3-(imidazolyl)-2-alkoxypropanoic acids PFIZER INC 2004-03-30 — — US disclosed
US-20030199522-A1 3-(Imidazolyl)-2-alkoxypropanoic acids PFIZER INC. 2003-10-23 — — US disclosed
WO-2003061652-A1 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS PFIZER LIMITED (GB) 2003-07-31 — — WO disclosed
WO-2003061652-A1 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS PFIZER LIMITED (GB) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199522-A1 3-(Imidazolyl)-2-alkoxypropanoic acids F2, FGB, F7 SMN1; SMN2 2304/4885GAA 4272/4885CMA1 1500/4885
US-12297187-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B SMN1; SMN2 4622/4885GAA 2387/4885CMA1 732/4885
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B SMN1; SMN2 4622/4885GAA 2387/4885CMA1 732/4885
US-20240150362-A1 Substituted Pyrrolotriazines USP7, UBA7, USP5 SMN1; SMN2 2350/4885GAA 733/4885CMA1 1015/4885
US-20050250775-A1 Novel compounds OPRL1, UGT1A1, NPSR1 SMN1; SMN2 8/4885GAA 1103/4885CMA1 1245/4885
US-20040254164-A1 3-(imidazolyl)-2-alkoxypropanoic acids F2, FGB, F7 SMN1; SMN2 2414/4885GAA 4279/4885CMA1 1445/4885
US-11512067-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B SMN1; SMN2 4622/4885GAA 2387/4885CMA1 732/4885
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B SMN1; SMN2 4622/4885GAA 2387/4885CMA1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.